Cargando…

A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro

We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Mary Hongying, Porritt, Rebecca A., Rivas, Magali Noval, Krieger, James M., Ozdemir, Asli Beyza, Garcia, Gustavo, Arumugaswami, Vaithilingaraja, Fries, Bettina C., Arditi, Moshe, Bahar, Ivet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082696/
https://www.ncbi.nlm.nih.gov/pubmed/33930306
http://dx.doi.org/10.1016/j.str.2021.04.005
_version_ 1783685890718040064
author Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M.
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
author_facet Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M.
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
author_sort Cheng, Mary Hongying
collection PubMed
description We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif at its polybasic (PRRA) insert to inhibit infection in live virus assays. The overlap between the superantigenic site of the spike and its proteolytic cleavage site suggests that the mAb prevents viral entry by interfering with the proteolytic activity of cell proteases (furin and TMPRSS2). The high affinity of 6D3 for this site originates from a polyacidic segment at its heavy chain CDR2. The study points to the potential utility of 6D3 for possibly treating COVID-19, MIS-C, or common colds caused by human coronaviruses that also possess a furin-like cleavage site.
format Online
Article
Text
id pubmed-8082696
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-80826962021-04-29 A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M. Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet Structure Article We recently discovered a superantigen-like motif sequentially and structurally similar to a staphylococcal enterotoxin B (SEB) segment, near the S1/S2 cleavage site of the SARS-CoV-2 spike protein, which might explain the multisystem inflammatory syndrome (MIS-C) observed in children and the cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif at its polybasic (PRRA) insert to inhibit infection in live virus assays. The overlap between the superantigenic site of the spike and its proteolytic cleavage site suggests that the mAb prevents viral entry by interfering with the proteolytic activity of cell proteases (furin and TMPRSS2). The high affinity of 6D3 for this site originates from a polyacidic segment at its heavy chain CDR2. The study points to the potential utility of 6D3 for possibly treating COVID-19, MIS-C, or common colds caused by human coronaviruses that also possess a furin-like cleavage site. Elsevier Ltd. 2021-09-02 2021-04-29 /pmc/articles/PMC8082696/ /pubmed/33930306 http://dx.doi.org/10.1016/j.str.2021.04.005 Text en © 2021 Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M.
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_full A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_fullStr A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_full_unstemmed A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_short A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_sort monoclonal antibody against staphylococcal enterotoxin b superantigen inhibits sars-cov-2 entry in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082696/
https://www.ncbi.nlm.nih.gov/pubmed/33930306
http://dx.doi.org/10.1016/j.str.2021.04.005
work_keys_str_mv AT chengmaryhongying amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT porrittrebeccaa amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT rivasmagalinoval amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT kriegerjamesm amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT ozdemiraslibeyza amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT garciagustavo amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arumugaswamivaithilingaraja amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT friesbettinac amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arditimoshe amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT baharivet amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT chengmaryhongying monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT porrittrebeccaa monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT rivasmagalinoval monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT kriegerjamesm monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT ozdemiraslibeyza monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT garciagustavo monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arumugaswamivaithilingaraja monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT friesbettinac monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arditimoshe monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT baharivet monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro